These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 22972646)

  • 1. Vascular burden and Alzheimer disease pathologic progression.
    Lo RY; Jagust WJ;
    Neurology; 2012 Sep; 79(13):1349-55. PubMed ID: 22972646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cognitive reserve markers on Alzheimer pathologic progression.
    Lo RY; Jagust WJ;
    Alzheimer Dis Assoc Disord; 2013; 27(4):343-50. PubMed ID: 23552443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities.
    Tosto G; Zimmerman ME; Carmichael OT; Brickman AM;
    JAMA Neurol; 2014 Jul; 71(7):872-7. PubMed ID: 24821476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism.
    Haight TJ; Landau SM; Carmichael O; Schwarz C; DeCarli C; Jagust WJ;
    JAMA Neurol; 2013 Aug; 70(8):1039-45. PubMed ID: 23779022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal change of biomarkers in cognitive decline.
    Lo RY; Hubbard AE; Shaw LM; Trojanowski JQ; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
    Arch Neurol; 2011 Oct; 68(10):1257-66. PubMed ID: 21670386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
    J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy.
    Fiford CM; Manning EN; Bartlett JW; Cash DM; Malone IB; Ridgway GR; Lehmann M; Leung KK; Sudre CH; Ourselin S; Biessels GJ; Carmichael OT; Fox NC; Cardoso MJ; Barnes J;
    Hippocampus; 2017 Mar; 27(3):249-262. PubMed ID: 27933676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?
    Provenzano FA; Muraskin J; Tosto G; Narkhede A; Wasserman BT; Griffith EY; Guzman VA; Meier IB; Zimmerman ME; Brickman AM;
    JAMA Neurol; 2013 Apr; 70(4):455-61. PubMed ID: 23420027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topographical differences in white matter hyperintensity burden and cognition in aging, MCI, and AD.
    Kamal F; Morrison C; Maranzano J; Zeighami Y; Dadar M
    Geroscience; 2023 Feb; 45(1):1-16. PubMed ID: 36229760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort.
    Prasad K; Wiryasaputra L; Ng A; Kandiah N
    Dement Geriatr Cogn Disord; 2011; 31(6):431-4. PubMed ID: 21757908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting missing biomarker data in a longitudinal study of Alzheimer disease.
    Lo RY; Jagust WJ;
    Neurology; 2012 May; 78(18):1376-82. PubMed ID: 22491869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
    Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
    Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.